Rezultati pretraživanja
  1. prije 10 sati

    Coronavirus: How Companies Around The Globe Are Responding > our latest in with transcript quotes from and more

  2. 30. sij

    - Illumina, Inc. 2019 Q4 - Results - Earnings Call Presentation.

  3. 30. sij

    Coronavirus update: A new task force, quarantined Americans and WHO to decide if it’s a public health emergency

  4. 30. sij

    - Illumina: Strongly Positioned But That Merger Blow Has Raised Questions.

    1 proslijeđeni tweet
  5. 30. sij

    - Illumina's (ILMN) CEO Francis deSouza on Q4 2019 Results - Earnings Call Transcript.

    2 korisnika označavaju da im se sviđa
  6. 29. sij

    Illumina EPS beats by $0.12, beats on revenue

  7. 29. sij

    - Illumina Q4 earnings up 14%, full-year cash flow ops up 48%

    2 korisnika označavaju da im se sviđa
  8. 29. sij

    Q4 Non-GAAP EPS of $1.70 beats by $0.12; GAAP EPS of $1.61 beats by $0.16. • Revenue of $953M (+9.9% Y/Y) beats by $2.84M.

  9. 29. sij

    Illumina Q4 2019 Earnings Preview

  10. 28. sij

    - Illumina: Volatile Price May Be On A Downtrend With Q4 Results Due.

  11. 23. sij

    "Labs in China/Thailand have sequenced genomes of 19 strains... 'That’s pretty remarkable, given that we’re 2 weeks in,' says at . 'People are extremely fast/excellent w/ data sharing'"

    1 reply 2 proslijeđena tweeta 8 korisnika označava da im se sviđa
  12. 15. sij

    Illumina on growth in data being generated by customers.

    11 korisnika označava da im se sviđa
  13. 13. sij

    ICYMI: stock dropped today after its presentation at . asked CEO Francis deSouza about that and more in this EXCLUSIVE interview:

    4 proslijeđena tweeta 6 korisnika označava da im se sviđa
  14. 18. pro 2019.

    We are short - we see odds heavily stacked against Twist in upcoming early 2020 trial w/ Agilent; cash burn is out of control esp. w/ high 2020 litigation expense; and FTC suit should take deflate M&A hope

    6 proslijeđenih tweetova 15 korisnika označava da im se sviđa
  15. 17. pro 2019.

    The FTC blocks 's deal, calling DNA sequencing giant "a monopolist."

    19 proslijeđenih tweetova 26 korisnika označava da im se sviđa
  16. 13. lis 2019.

    The IPO appetite isn't there, it's last post-money round was a ridiculous multiple of sales & is eating its lunch, so why isn't NASDAQ IPO material? Neil Woodford’s plan to float Oxford Nanopore looks like a daydream’' | via

    1 reply 2 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
  17. 9. lis 2019.

    A look at 's shrewd deal with , and what investors are looking for from the DNA sequencing giant. (Paywall.)

    8 proslijeđenih tweetova 9 korisnika označava da im se sviđa
  18. 30. srp 2019.

    Illumina even more downbeat about near-term prospects for a turnaround in the direct-to-consumer market.

    4 korisnika označavaju da im se sviđa
  19. 12. srp 2019.

    👀 ⁦⁩ on $ILMN’s earnings:

    3 proslijeđena tweeta 4 korisnika označavaju da im se sviđa
  20. 18. lip 2019.

    Genomic testing stocks in play: and Invitae (I own the latter two)

    5 proslijeđenih tweetova 1 korisnik označava da mu se sviđa

Nema rezultata.

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.